Physiomics plc announces today that following the receipt of notice of exercise of employee options, 2,925,000 Ordinary Shares of 0.04p each in the Company (the "Options Shares") have now been issued at a price of 0.15p each.
Application has been made to admit the Option Shares to trading on AIM, and dealings in the Option Shares are expected to commence on 1 April 2011.
Following the issue of the Option Shares, the total number of shares now in issue is 1,002,150,074 Ordinary Shares.
Dr. Mark Chadwick, CEO
+44 (0)1865 784980
WH Ireland Limited
+44 (0) 161 832 2174
Information on Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behavior to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCellŽ technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCellŽ is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.